1.Response of Human Renal Cell Carcinoma Cells to Bone Morphogenetic Proteins, and the Expression of Bone Morphogenetic Protein Receptors.
Dong Hyeon LEE ; Jun Ho CHUNG ; Isaac Yi KIM
Korean Journal of Urology 2003;44(2):160-167
PURPOSE: Bone morphogenetic protein (BMP) is a pleiotropic growth factor, which has been suggested to play a critical role during the development and homeostasis of the kidney. We evaluated the response of the human renal cell carcinoma (RCC) cell lines to BMPs. MATERIALS AND METHODS: We evaluated the growth rate of the human RCC cell lines, 112, 117 and 181, according to the concentrations of BMP-4, -6 and -7, and detected the levels of the BMP receptors (BMPRs) expressed in the cell lines. To demonstrate that the defect in BMP-6 signaling is at the receptor level, BMP-6 resistant cell lines were transfected, with adenovirus containing the constitutively active form of the BMP receptor types II (BMPR-II). After transfection, the cells were transfected with pSBE4, the construct of the BMP-6-responsive luciferase reporter gene, and a luciferase assay performed. RESULTS: The BMP-6 inhibited the proliferation of the 112, but not those of the 117 and 181 cells, in a dose-dependent manner. From Northern blot and immunoblot analyses, it was demonstrated that the 117 and 181 cells had undetectable levels of BMPR-II expression. The levels of luciferase activity, following adenovirus infections, was elevated in both the 117 and 181 cells, suggesting that the down-stream signaling molecules of the BMP-6 was intact in these cell lines. CONCLUSIONS: Taken together, these results demonstrate that the human RCC cell lines 117 and 181 are resistant to the growth inhibitory effects of the BMP-6 due to their decreased levels of BMPR-II expression.
Adenoviridae
;
Adenoviridae Infections
;
Blotting, Northern
;
Bone Morphogenetic Protein 6
;
Bone Morphogenetic Protein Receptors*
;
Bone Morphogenetic Proteins*
;
Carcinoma, Renal Cell*
;
Cell Line
;
Genes, Reporter
;
Homeostasis
;
Humans*
;
Kidney
;
Luciferases
;
Transfection
2.Telomerase activity: a potential marker of bladder transitional cell carcinoma in bladder washes.
Seung Choul YANG ; Dong Hyeon LEE ; Sung Joon HONG ; Byung Ha CHUNG ; Isaac Yi KIM
Yonsei Medical Journal 1997;38(3):155-159
The enzyme telomerase maintains a constant telomere length in immortalized cells, allowing unlimited cell proliferation. Almost all cancer cells express telomerase activity. However, little data is available regarding the role of telomerase activity in the detection of bladder cancer with a bladder wash specimen. We detected telomerase activity in a bladder wash specimen of bladder cancer and normal tissues, and compared them with final pathologic diagnosis. Twenty-three patients with transitional cell carcinoma (TCC) of the bladder were enrolled in our study. A bladder wash specimen was obtained before transurethral resection of the bladder (TURB) and normal and cancer tissues from the same patients during TURB. Telomerase activity was analyzed in each specimen a using telomeric repeat amplification protocol (TRAP) assay based on polymerase chain reaction (PCR) technique. Cytologic diagnosis was performed using Papanicolaou's stain with cytocentrifuged cytology preparation. We observed telomerase activity in 95.7% (22/23) of bath cancer tissues and bladder wash specimens; only one case did not express telomerase activity. Telomerase activity was undetected in all normal tissues except one, which was obtained from a patient with carcinoma in situ. A total of 69.6% (16/23) of wash specimens were positive in cytopathologic diagnosis. The accuracy of cytopathologic diagnosis in pathologic grade 2 or 3 was relatively high (83.3%, 15/18). However, in five cases of grade 1 TCC only 20% (1/5) of cytologic diagnosis was positive whereas the telomerase activity of wash specimens was detected in 80% (4/5). Our data demonstrates that not only the majority of human bladder cancer tissues, but also the bladder wash specimens obtained from patients with TCC, expressed telomerase activity. It indicates that telomerase activity may be a reliable marker in detecting bladder cancer especially in cases with a low grade that bladder wash cytology can miss.
Aged
;
Aged, 80 and over
;
Bladder Neoplasms/enzymology*
;
Carcinoma, Transitional Cell/metabolism*
;
Female
;
Human
;
Irrigation
;
Male
;
Middle Age
;
Telomerase/metabolism*
;
Tumor Markers, Biological
3.Novel Combination Markers for Predicting Survival in Patients with Muscle Invasive Bladder Cancer: USP18 and DGCR2.
Ye Hwan KIM ; Won Tae KIM ; Pildu JEONG ; Yun Sok HA ; Ho Won KANG ; Seok Joong YUN ; Sung Kwon MOON ; Yung Hyun CHOI ; Isaac Yi KIM ; Wun Jae KIM
Journal of Korean Medical Science 2014;29(3):351-356
We performed gene expression profiling in bladder cancer patients to identify cancer-specific survival-related genes in muscle invasive bladder cancer (MIBC) patients. Sixty-two patients with MIBC were selected as the original cohort and another 118 MIBC patients were chosen as a validation cohort. The expression of USP18, DGCR2, and ZNF699 genes were measured and we analyzed the association between gene signatures and survival. USP18 and DGCR2, were significantly correlated to cancer-specific death (P=0.020, P=0.007, respectively). Cancer-specific survival in the low USP18 or DGCR2 expression group was significantly longer than the high expression group (P=0.018, P=0.006, respectively). In multivariate Cox regression analysis, a combination of USP18 and DGCR2 mRNA expression levels were significant risk factors for cancer-specific death (HR, 2.106; CI, 1.043-4.254, P=0.038). Overall survival and cancer-specific survival rates in the low-combination group were significantly longer than those in the high-expression group (P=0.001, both). In conclusion, decreased expressions of USP18 and DGCR2 were significantly associated with longer cancer-specific survival, and also the combination of two genes was correlated to a longer survival for MIBC patients. Thus, the combination of USP18 and DGCR2 expression was shown to be a reliable prognostic marker for cancer-specific survival in MIBC.
Adult
;
Aged
;
Aged, 80 and over
;
Biological Markers/metabolism
;
Carrier Proteins/genetics/metabolism
;
Endopeptidases/genetics/*metabolism
;
Female
;
Gene Expression Profiling
;
Humans
;
Kaplan-Meier Estimate
;
Male
;
Middle Aged
;
Muscle Neoplasms/*secondary
;
Neoplasm Invasiveness
;
Neoplasm Staging
;
Platelet Glycoprotein GPIb-IX Complex/genetics/*metabolism
;
Predictive Value of Tests
;
ROC Curve
;
Regression Analysis
;
Risk Factors
;
Urinary Bladder Neoplasms/*diagnosis/metabolism/*mortality/pathology
4.Diagnostic Role of Prostate Resection in the Elderly Patients Who Experience Significant Co-Morbidity with a High Clinical Suspicion of Prostate Cancer.
Ho Won KANG ; Jin Bak YANG ; Whi An KWON ; Young Suk LEE ; Won Tae KIM ; Yong June KIM ; Seok Joong YUN ; Sang Cheol LEE ; Isaac Yi KIM ; Wun Jae KIM
Journal of Korean Medical Science 2013;28(12):1796-1800
The necessity of routine prostate biopsy prior to transurethral resection of the prostate (TURP) in elderly comorbid patients with a high prostate specific antigen (PSA) level remains controversial. We assessed the role of TURP in prostate cancer diagnosis in these individuals. A total of 197 patients underwent TURP in conjunction with prostatic needle biopsy. Pathologic reviews of specimens of TUR chips and biopsy cores were analyzed. Overall, prostate cancer (CaP) was detected in 114 patients (57.6%). Ninety-eight cancers (86%) were detected with TURP and biopsy, and seven cancers (6.1%) with only TURP. The Gleason score of a TUR-specimen was identical to that of the biopsy-core in 43.9% of cases. Variables associated with diagnostic accuracy in the TUR-specimens included the prebiopsy PSA level, prostate specific antigen density (PSAD), and the Gleason score in biopsy cores. In patients with a PSA level and a PSAD that was greater than 15.4 ng/mL and 0.69 ng/mL/g, respectively, 100% of the cancers were detected in the TUR-specimens. Our results suggest that a prostatic biopsy might be omitted prior to TURP in elderly patients with significant co-morbidity and levels for PSA of >15.4 ng/mL.
Aged
;
Aged, 80 and over
;
Area Under Curve
;
Biopsy, Needle
;
Comorbidity
;
Humans
;
Male
;
Neoplasm Grading
;
Prostate/*surgery
;
Prostate-Specific Antigen/*blood
;
Prostatic Neoplasms/*diagnosis/epidemiology/*pathology/surgery
;
ROC Curve
;
Transurethral Resection of Prostate
5.Prostate Size Correlates with Fasting Blood Glucose in Non-Diabetic Benign Prostatic Hyperplasia Patients with Normal Testosterone Levels.
Won Tae KIM ; Seok Joong YUN ; Young Deuk CHOI ; Gi Young KIM ; Sung Kwon MOON ; Yung Hyun CHOI ; Isaac Yi KIM ; Wun Jae KIM
Journal of Korean Medical Science 2011;26(9):1214-1218
We evaluated the correlations between BMI, fasting glucose, insulin, testosterone level, insulin resistance, and prostate size in non-diabetic benign prostatic hyperplasia (BPH) patients with normal testosterone levels. Data from 212 non-diabetic BPH patients with normal testosterone levels, who underwent transurethral resection of the prostate (TURP) due to medical treatment failure, were evaluated retrospectively. Patients with prostate specific antigen (PSA) levels of > or = 3 ng/mL underwent multicore transrectal prostate biopsy before TURP to rule out prostate cancer. Patients with diabetes mellitus (DM) or serum testosterone levels of < 3.50 ng/mL were excluded from analysis. Correlations between clinical and laboratory parameters were determined. Prostate size correlated positively with age (r = 0.227, P < 0.001), PSA (r = 0.510, P < 0.001), and fasting glucose level (r = 0.186, P = 0.007), but not with BMI, testosterone, insulin level, or insulin resistance (each P > 0.05). Testosterone level inversely correlated with BMI (r = -0.327, P < 0.001), insulin level (r = -0.207, P = 0.003), and insulin resistance (r = -0.221, P = 0.001), but not with age, prostate size, PSA, or fasting glucose level (each P > 0.05). Upon multiple adjusted linear regression analysis, prostate size correlated with elevated PSA (P < 0.001) and increased fasting glucose levels (P = 0.023). In non-DM BPH patients with normal testosterone levels, fasting glucose level is an independent risk factor for prostate hyperplasia.
Age Factors
;
Aged
;
Blood Glucose/*analysis
;
Body Mass Index
;
Humans
;
Insulin/blood
;
Insulin Resistance
;
Linear Models
;
Male
;
Middle Aged
;
Organ Size
;
Prostate/*anatomy & histology
;
Prostate-Specific Antigen/blood
;
Prostatic Hyperplasia/metabolism/*pathology
;
Retrospective Studies
;
Risk Factors
;
Testosterone/*blood
6.Primary Androgen Deprivation Therapy for Prostate Cancer in Koreans: A Retrospective Multicenter Study.
Won Ik SEO ; Pil Moon KANG ; Tae Hyo KIM ; Kyung Hyun MOON ; Jae Min CHUNG ; Dong Hyun LEE ; Isaac Yi KIM ; Kweonsik MIN ; Jaeil CHUNG ; Wansuk KIM ; Dong Il KANG
The World Journal of Men's Health 2014;32(3):159-166
PURPOSE: To evaluate the characteristics of patients who received primary androgen deprivation therapy (PADT) for prostate cancer and the clinical efficacy of this treatment. MATERIALS AND METHODS: Two hundred forty patients treated by PADT were reviewed. These patients could not receive definitive therapy owing to old age, patient need, and medical comorbidity. The patients were divided into three groups according to the extent of prostate cancer: localized, locally advanced, and metastatic. Then, prostate-specific antigen (PSA) progression in these groups was analyzed. RESULTS: The median age of the patients was 73.0 years, and the median pretreatment PSA level was 47.0 ng/mL. Of the patients, 91.7% were treated with combined androgen blockade, and 8.3% were treated with monotherapy. Clinical factors for PSA progression were a PSA nadir and a high clinical stage. Estimated PSA recurrence-free median survival time in each group was 57, 24, and 12 months, respectively. A PSA nadir of >0.2 ng/mL and metastatic stage were independent factors for expecting a poor response to PADT (hazard ratio 4.26, p<0.001; and 2.60, p<0.001). CONCLUSIONS: Patients with localized or locally advanced prostate cancer who did not receive definitive therapy had lower PSA progression rates than those at metastatic stage during PADT. Further, a PSA nadir of < or =0.2 ng/mL showed better progression-free survival. Therefore, PADT can be another therapeutic option in well-selected patients with localized or locally advanced prostate cancer and PSA change should be checked carefully.
Androgen Antagonists
;
Comorbidity
;
Disease-Free Survival
;
Humans
;
Prostate
;
Prostate-Specific Antigen
;
Prostatic Neoplasms*
;
Retrospective Studies*
7.GSTM1 Tissue Genotype as a Recurrence Predictor in Non-muscle Invasive Bladder Cancer.
Yun Sok HA ; Chunri YAN ; Pildu JEONG ; Won Tae KIM ; Seok Joong YUN ; Isaac YI KIM ; Sung Kwon MOON ; Wun Jae KIM
Journal of Korean Medical Science 2011;26(2):231-236
Tissue genotyping is more useful approach than using blood genomic DNA, which can reflect the effects of the somatic mutations in cancer. Although polymorphisms in glutathione S-transferase (GST) have been associated with the risk of bladder cancer (BC) development, few reports provide information about the prognosis of BC. We investigated glutathione S-transferase mu (GSTM1) and glutathione S-transferase theta (GSTT1) genotypes using genomic DNA from primary 165 BC tissue samples to assess the association with disease prognosis. DNA samples from tumor were analyzed by multiplex polymerase chain reaction (PCR). The results were compared with clinicopathological parameters. The prognostic significance of the GSTs was evaluated by Kaplan-Meier and multivariate Cox regression model. Kaplan-Meier estimates revealed significant differences in time to tumor recurrence according to the GSTM1 tissue genotype (P = 0.038) in non-muscle invasive bladder cancer (NMIBC). Multivariate Cox regression analysis also revealed that the tissue GSTM1 genotype (hazards ratio [HR]: 0.377, P = 0.031) was an independent predictor of bladder tumor recurrence in NMIBC. This identification of GSTM1 tissue genotype as a prognosticator for determining recurrence in NMIBC should prove highly useful in a clinical setting.
Aged
;
*Genotype
;
Glutathione Transferase/*genetics
;
Humans
;
Isoenzymes/*genetics
;
Kaplan-Meier Estimate
;
Middle Aged
;
Prognosis
;
Proportional Hazards Models
;
Recurrence
;
Tumor Markers, Biological/metabolism
;
Urinary Bladder Neoplasms/diagnosis/*genetics/pathology/*prevention & control
8.Clinical Significance of Wnt/beta-Catenin Signalling and Androgen Receptor Expression in Prostate Cancer.
Soo Jin JUNG ; Sangtaek OH ; Geun Taek LEE ; Jaeil CHUNG ; Kweonsik MIN ; Jangho YOON ; Wansuk KIM ; Dong Soo RYU ; Isaac Yi KIM ; Dong Il KANG
The World Journal of Men's Health 2013;31(1):36-46
PURPOSE: To investigate the relationships among the Wnt/beta-catenin pathway, androgen receptor (AR), and clinicopathological factors in hormone-naive prostate cancer. MATERIALS AND METHODS: This study was conducted with132 cases of hormone-naive prostate cancer treated by prostatectomy and prostate needle biopsy. An immunohistochemical study using antibodies against beta-catenin, matrix metalloproteinase-7 (MMP-7), and the AR was performed. For the in vitro study, PC-3, LNCaP, 22Rv1, and DU145 cell lines were used. RESULTS: The clinical or pathological stage ware a localized cancer in 36 patients (27.3%), locally advanced cancer in 31 (23.5%), and metastatic cancer in 65 (49.2%). We detected increased beta-catenin, AR, and MMP-7 expression with a high Gleason grade, disease progression, and increasing serum prostate-specific antigen (PSA) levels (p<0.01). In Spearman's rank correlations, the expression of cytoplasmic beta-catenin, MMP-7, and the AR were found to be significantly positively correlated. In addition, the expression of beta-catenin, MMP-7, and the AR were significantly correlated with clinicopathological variables indicative of a poor prognosis. Forty-nine patients with primary androgen deprivation had short response durations from hormone therapy to PSA progression with elevated MMP-7 expression on the Kaplan-Meier curve (p=0.0036). CONCLUSIONS: These data show that an activated Wnt/beta-catenin pathway and AR expression in prostate cancer are correlated with metastasis and aggressiveness. In addition, the expression of MMP-7 protein, a target of the Wnt/beta-catenin pathway, is associated with PSA progression in prostate cancer patients undergoing primary hormone therapy.
Antibodies
;
beta Catenin
;
Biopsy, Needle
;
Cell Line
;
Cytoplasm
;
Disease Progression
;
Humans
;
Matrix Metalloproteinase 7
;
Matrix Metalloproteinases
;
Neoplasm Metastasis
;
Prognosis
;
Prostate
;
Prostate-Specific Antigen
;
Prostatectomy
;
Prostatic Neoplasms
;
Receptors, Androgen
9.Impact of Posterior Urethral Plate Repair on Continence Following Robot-Assisted Laparoscopic Radical Prostatectomy.
Isaac Yi KIM ; Eun A HWANG ; Chinedu MMEJE ; Matthew ERCOLANI ; Dong Hyeon LEE
Yonsei Medical Journal 2010;51(3):427-431
PURPOSE: The objective of this study is to evaluate the continence rate following reconstruction of the posterior urethral plate in robot-assisted laparoscopic radical prostatectomy (RLRP). MATERIALS AND METHODS: A retrospective analysis of 50 men with clinically localized prostate cancer who underwent RLRP was carried out. Twenty-five patients underwent RLRP using the reconstruction of the posterior aspect of the rhabdosphincter (Rocco repair). Results of 25 consecutive patients who underwent RLRP prior to the implementation of the Rocco repair were used as the control. Continence was assessed at 7, 30, 90, and 180 days following foley catheter removal using the EPIC questionnaire as well as a follow-up interview with the surgeon. RESULTS: There was no statistically significant difference between the two groups in any of the patient demographics. At 7 days, the Rocco experimental group had a continence rate of 19% vs. 38.1% in the non-Rocco control group (p = 0.306). At 30 days, the continence rate in the Rocco group was 76.2% vs. 71.4% in the non-Rocco group (p = 1). At 90 days, the values were 88% vs. 80% (p = 0.718), respectively. At 180 days, the pad-free rate was 96% in both groups. CONCLUSION: Rocco repair offers no significant advantage in the time to recovery of continence following RLRP when continence is defined as the use of zero pads per day. On the other hand, Rocco repair was associated with increased incidence of urinary retention requiring prolonged foley catheter placement.
Aged
;
Humans
;
Laparoscopy/adverse effects/*methods
;
Male
;
Middle Aged
;
Prostatectomy/adverse effects/*methods
;
Retrospective Studies
;
Urethra/*surgery
;
Urinary Incontinence/*epidemiology/surgery
10.Bone Morphogenetic Protein Signaling: Implications in Urology.
Jeongyun JEONG ; Dong Il KANG ; Geun Taek LEE ; Isaac Yi KIM
Korean Journal of Urology 2010;51(8):511-517
The bone morphogenetic proteins (BMPs), as members of the transforming growth factor-beta (TGF-beta) superfamily, not only control bone formation, but also regulate multiple key steps during embryonic development and differentiation. Furthermore, BMPs play critical roles in maintaining the homeostasis of the cardiovascular, pulmonary, reproductive, urogenital, and nervous systems in adult life. Like all members of the TGF-beta superfamily, BMP signaling is mediated through a heteromeric complex of type I and type II transmembrane serine/threonine kinase receptors. The subsequent signal transduction cascade includes either the canonical Smad-dependent or non-canonical Smad-independent pathways. Reflecting the critical function of BMPs, BMP signaling is tightly regulated at multiple steps by various mechanisms including extracellular endogenous antagonists, neutralizing antibodies/extracellular soluble receptor domains, small molecule inhibitors, cytoplasmic inhibitory Smads, and transcriptional co-repressors. Recently, dorsomorphin, the first small molecule inhibitor of BMP signaling, was identified and suggested as a useful tool for dissecting the mechanisms of signaling pathways and for developing novel therapeutics for diverse human diseases that are related to the BMP signaling pathways. In this article, we discuss various mechanisms involved in regulating BMP signaling pathways and their implications for urology.
Adult
;
Bone Morphogenetic Proteins
;
Co-Repressor Proteins
;
Cytoplasm
;
Embryonic Development
;
Female
;
Homeostasis
;
Humans
;
Nervous System
;
Osteogenesis
;
Phosphotransferases
;
Pregnancy
;
Pyrazoles
;
Pyrimidines
;
Signal Transduction
;
Transforming Growth Factor beta
;
Transforming Growth Factors
;
Urology